Susquehanna International Group
RIGL icon

Susquehanna International Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Susquehanna International Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
39,100
+13,900
+55% +$467K ﹤0.01% 7752
2025
Q4 		$1.08M Sell
25,200
-4,800
-16% -$181K ﹤0.01% 7010
2025
Q3 		$850K Buy
+30,000
New +$897K ﹤0.01% 7730
2025
Q2 		– Sell
-10,100
Closed -$182K – 13562
2025
Q1 		$182K Buy
+10,100
New +$205K ﹤0.01% 11046
2024
Q4 		– Sell
-432,400
Closed -$7M – 13046
2024
Q3 		$7M Sell
432,400
-3,600
-0.8% -$42.3K ﹤0.01% 3091
2024
Q2 		$3.58M Buy
436,000
+432,950
+14,195% +$4.53M ﹤0.01% 3988
2024
Q1 		$45.1K Sell
3,050
-400
-12% -$5.39K ﹤0.01% 11591
2023
Q4 		$50K Sell
3,450
-1,690
-33% -$17.3K ﹤0.01% 11713
2023
Q3 		$55.5K Sell
5,140
-1,790
-26% -$21.5K ﹤0.01% 11253
2023
Q2 		$89.4K Buy
6,930
+3,510
+103% +$47.5K ﹤0.01% 11031
2023
Q1 		$45.1K Buy
+3,420
New +$54.3K ﹤0.01% 11737
2022
Q4 		– Sell
-2,260
Closed -$27K – 13480
2022
Q3 		$27K Sell
2,260
-430
-16% -$5.82K ﹤0.01% 12492
2022
Q2 		$30K Sell
2,690
-290
-10% -$5.82K ﹤0.01% 12223
2022
Q1 		$89K Sell
2,980
-6,530
-69% -$177K ﹤0.01% 11987
2021
Q4 		$252K Sell
9,510
-3,390
-26% -$102K ﹤0.01% 10918
2021
Q3 		$468K Sell
12,900
-3,540
-22% -$139K ﹤0.01% 9573
2021
Q2 		$713K Buy
16,440
+3,140
+24% +$119K ﹤0.01% 8696
2021
Q1 		$455K Sell
13,300
-6,240
-32% -$247K ﹤0.01% 9703
2020
Q4 		$684K Sell
19,540
-25,480
-57% -$738K ﹤0.01% 7605
2020
Q3 		$1.08M Buy
+45,020
New +$1.11M ﹤0.01% 5924
2020
Q2 		– Sell
-2,910
Closed -$45K – 10786
2020
Q1 		$45K Buy
2,910
+490
+20% +$10.4K ﹤0.01% 9723
2019
Q4 		$52K Buy
2,420
+230
+11% +$4.74K ﹤0.01% 9333
2019
Q3 		$41K Sell
2,190
-2,930
-57% -$60.5K ﹤0.01% 9834
2019
Q2 		$134K Buy
5,120
+2,580
+102% +$58.2K ﹤0.01% 9457
2019
Q1 		$65K Sell
2,540
-12,180
-83% -$278K ﹤0.01% 8407
2018
Q4 		$339K Sell
14,720
-2,150
-13% -$60.7K ﹤0.01% 6778
2018
Q3 		$542K Buy
16,870
+8,900
+112% +$267K ﹤0.01% 6364
2018
Q2 		$226K Sell
7,970
-38,550
-83% -$1.37M ﹤0.01% 8379
2018
Q1 		$1.65M Buy
46,520
+41,480
+823% +$1.66M ﹤0.01% 4286
2017
Q4 		$196K Buy
5,040
+3,560
+241% +$135K ﹤0.01% 8297
2017
Q3 		$38K Buy
1,480
+320
+28% +$7.78K ﹤0.01% 8585
2017
Q2 		$32K Sell
1,160
-1,110
-49% -$30.4K ﹤0.01% 8968
2017
Q1 		$75K Sell
2,270
-6,790
-75% -$173K ﹤0.01% 8494
2016
Q4 		$216K Buy
9,060
+2,300
+34% +$65.9K ﹤0.01% 8544
2016
Q3 		$248K Buy
6,760
+5,600
+483% +$161K ﹤0.01% 7234
2016
Q2 		$26K Buy
+1,160
New +$28.8K ﹤0.01% 8349
2015
Q3 		– Sell
-4,430
Closed -$142K – 10073
2015
Q2 		$142K Buy
+4,430
New +$169K ﹤0.01% 9515
2014
Q2 		– Sell
-2,700
Closed -$105K – 10046
2014
Q1 		$105K Sell
2,700
-5,810
-68% -$207K ﹤0.01% 8549
2013
Q4 		$243K Sell
8,510
-550
-6% -$16.1K ﹤0.01% 7937
2013
Q3 		$324K Buy
9,060
+5,720
+171% +$209K ﹤0.01% 7094
2013
Q2 		$112K Buy
+3,340
New +$151K ﹤0.01% 7744

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's RIGL Position: Q1 2026 in Review

Susquehanna International Group increased its Rigel Pharmaceuticals (RIGL) stake by 171% in Q1 2026, buying an estimated $652K and bringing the position to 30,790 shares worth $833K. The position accounts for ﹤0.01% of the portfolio, ranked #8378.

Susquehanna International Group first reported a position in RIGL in Q2 2013 and has held it in 48 quarters since. The position peaked at $2.05M in Q2 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Susquehanna International Group held 30,790 shares of Rigel Pharmaceuticals worth $833K as of Q1 2026.
  • Susquehanna International Group bought 19,409 Rigel Pharmaceuticals shares in Q1 2026, an estimated $652K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8378 holding.
  • Susquehanna International Group first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
  • Susquehanna International Group's Rigel Pharmaceuticals position peaked at $2.05M in Q2 2021.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.